RG7916
Phase 2
RocheRG7916 is one of 111 therapeutic programs targeting Angioedema. It is currently in Phase 2.
4
Indications
0
Total Trials
0
Active Trials
110
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Cimzia
UCBPreclinical
Simponi
Johnson & JohnsonPreclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ilaris
NovartisPreclinical
RG7916
RochePhase 2
Celexa
AbbViePreclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Cataflam
NovartisPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for RG7916. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company